BS
BSX.US Boston Scientific Corp
- Market cap
- USD 64.3B
- P/E
- 18.7x
- P/B
- 2.50x
- ROE
- 14.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is BSX.US undervalued?
Graham numberBSX.US trades 44.2% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Boston Scientific Corp fundamental analysis
No fundamental analysis for Boston Scientific Corp yet.
Boston Scientific Corp stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Boston Scientific Corp
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scopes used for diagnostic and therapeutic procedures in the pa…
Full company profileBoston Scientific Corp financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Boston Scientific Corp annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 8.39B | 9.05B | 9.82B | 10.7B | 9.91B | 11.9B | 12.7B | 14.2B | 16.7B | 20.1B | 21.0B |
| Gross Profit | 5.34B | 5.87B | 6.48B | 6.88B | 5.58B | 7.46B | 7.71B | 8.83B | 10.3B | 13.9B | 14.5B |
| Operating Income | 1.24B | 1.53B | 1.74B | 1.71B | 601M | 1.92B | 1.82B | 2.18B | 2.64B | 3.97B | 4.31B |
| EBITDA | 1.23B | 2.01B | 2.59B | 2.21B | 1.51B | 2.52B | 2.74B | 3.45B | 3.94B | 5.10B | 5.46B |
| Net Income | 347M | 104M | 1.67B | 4.70B | -82.0M | 1.04B | 698M | 1.59B | 1.85B | 2.89B | 3.76B |
| EPS | 0.25 | 0.07 | 1.19 | 3.33 | -0.06 | 0.73 | 0.48 | 1.09 | 1.25 | 1.93 | 2.59 |
| Balance Sheet | |||||||||||
| Total Assets | 18.1B | 19.0B | 21.0B | 30.6B | 30.8B | 32.2B | 32.5B | 35.1B | 39.4B | 43.7B | 45.5B |
| Total Liabilities | 11.4B | 12.0B | 12.3B | 16.7B | 15.5B | 15.6B | 14.9B | 15.6B | 17.4B | 19.2B | 19.6B |
| Shareholders' Equity | 6.73B | 7.01B | 8.73B | 13.9B | 15.3B | 16.6B | 17.6B | 19.3B | 21.8B | 24.2B | 25.6B |
| Cash & Short-term Investments | 196M | 188M | 146M | 217M | 1.73B | 1.93B | 928M | 865M | 414M | 2.05B | 609M |
| Total Debt | 5.48B | 5.62B | 7.06B | 10.3B | 9.54B | 9.45B | 9.28B | 9.49B | 11.1B | 12.4B | 12.0B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 972M | 1.43B | 310M | 1.84B | 1.51B | 1.87B | 1.53B | 2.50B | 3.44B | 4.53B | 3.83B |
| Capital Expenditure | 376M | 319M | 316M | 461M | 376M | 554M | 612M | 800M | 790M | 876M | 736M |
| Free Cash Flow | 596M | 1.11B | -6.00M | 1.38B | 1.13B | 1.32B | 914M | 1.70B | 2.65B | 3.66B | 3.09B |
| Ratios | |||||||||||
| ROE | 5.2% | 1.5% | 19.2% | 33.9% | -0.5% | 6.3% | 4.0% | 8.3% | 8.5% | 11.9% | 14.7% |
| ROA | 1.9% | 0.5% | 8.0% | 15.4% | -0.3% | 3.2% | 2.1% | 4.5% | 4.7% | 6.6% | 8.3% |
| Net Profit Margin | 4.1% | 1.1% | 17.0% | 43.8% | -0.8% | 8.7% | 5.5% | 11.2% | 11.1% | 14.4% | 17.9% |
| Debt to Equity | 0.81x | 0.80x | 0.81x | 0.74x | 0.62x | 0.57x | 0.53x | 0.49x | 0.51x | 0.51x | 0.47x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Boston Scientific Corp dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | USD 28.0M | 0.02 | 1.8% |
| 2022 | USD 55.0M | 0.04 | 7.9% |
| 2021 | USD 55.0M | 0.04 | 5.3% |
| 2020 | USD 28.0M | 0.02 | - |
| 2019 | USD 28.0M | 0.02 | 0.6% |
| 2018 | USD 28.0M | 0.02 | 1.7% |
| 2017 | USD 28.0M | 0.02 | 26.9% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 2:1 on Nov 6, 2003.
Who owns Boston Scientific Corp
- Insiders 0.27%
- Institutions 96.33%
- Public & others 3.41%
- Shares outstanding 1.45B
- Free float 1.44B
Top funds holding BSX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 46.0M | 3.17% | -2.61% | Sep 2026 |
| Vanguard 500 Index Investor | 38.1M | 2.63% | -3.64% | Sep 2026 |
| Vanguard PRIMECAP Inv | 35.8M | 2.47% | +15.96% | Sep 2026 |
| iShares Core S&P 500 ETF | 19.3M | 1.33% | +0.17% | Oct 2026 |
| Fidelity 500 Index | 18.8M | 1.30% | -2.38% | Sep 2026 |
| State Street® SPDR® S&P 500® ETF | 17.6M | 1.22% | -0.25% | Oct 2026 |
| Vanguard Health Care Inv | 15.8M | 1.09% | +40.02% | Sep 2026 |
| Vanguard MStar Mid Cap Index Instl | 15.5M | 1.07% | 0.00% | Sep 2026 |
| American Funds Growth Fd of Amer A | 14.2M | 0.98% | +26.07% | Sep 2026 |
| Vanguard MStar Value Index Investor | 13.8M | 0.95% | +94.41% | Sep 2026 |
| American Funds American Balanced A | 11.3M | 0.78% | 0.00% | Sep 2026 |
| Vanguard Capital Opportunity Inv | 10.6M | 0.73% | +20.16% | Sep 2026 |
| State Street®HlthCrSelSectSPDR®ETF | 10.6M | 0.73% | +0.88% | Oct 2026 |
| Dodge & Cox Stock I | 9.77M | 0.67% | 0.00% | Sep 2026 |
| MFS Value A | 9.32M | 0.64% | -2.89% | Sep 2026 |
| Strategic Advisers Fidelity US TtlStk | 7.69M | 0.53% | -14.35% | Sep 2026 |
| Vanguard Institutional Index I | 7.67M | 0.53% | -3.50% | Sep 2026 |
| Janus Henderson Enterprise D | 7.14M | 0.49% | 0.00% | Sep 2026 |
| American Funds New Economy A | 6.74M | 0.47% | +139.24% | Sep 2026 |
| Putnam Large Cap Value A | 6.08M | 0.42% | 0.00% | Sep 2026 |
Top institutions holding BSX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| BlackRock Inc | 130M | 8.95% | -1.62% | Jun 2026 |
| Vanguard Capital Management, LLC | 97.1M | 6.70% | +0.70% | Jun 2026 |
| State Street Corp | 70.1M | 4.84% | +3.12% | Jun 2026 |
| PRIMECAP Management Company | 50.5M | 3.49% | +55.31% | Jun 2026 |
| FMR Inc | 45.7M | 3.15% | -38.43% | Jun 2026 |
| Geode Capital Management, LLC | 33.4M | 2.31% | +0.46% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 29.8M | 2.06% | -0.01% | Jun 2026 |
| D. E. Shaw & Co LP | 25.5M | 1.76% | +4.71% | Jun 2026 |
| Massachusetts Financial Services Company | 24.9M | 1.72% | +126.06% | Jun 2026 |
| JPMorgan Chase & Co | 23.9M | 1.65% | -28.31% | Jun 2026 |
| Arrowstreet Capital Limited Partnership | 23.3M | 1.61% | +67.68% | Jun 2026 |
| NORGES BANK | 21.2M | 1.46% | -8.22% | Jun 2026 |
| Two Sigma Investments LLC | 19.4M | 1.34% | +105.70% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 18.9M | 1.31% | -14.91% | Jun 2026 |
| Jupiter Topco LLC | 18.8M | 1.30% | 0.00% | Jun 2026 |
| Bollard Group LLC | 18.4M | 1.27% | -0.60% | Jun 2026 |
| The Goldman Sachs Group Inc | 17.0M | 1.17% | -10.25% | Jun 2026 |
| Capital World Investors | 16.8M | 1.16% | +9.81% | Jun 2026 |
| UBS Group AG | 16.4M | 1.13% | +10.31% | Jun 2026 |
| Wellington Management Company LLP | 15.3M | 1.06% | -18.75% | Jun 2026 |
Boston Scientific Corp company profile
- Company name
- Boston Scientific Corp
- Ticker
- BSX.US
- Exchange
- USA Stocks
- Listed since
- May 18, 1992
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 59,000
- Fiscal year end
- December
- Address
- 300 Boston Scientific Way, Marlborough, MA, United States, 01752-1234
- Phone
- 508 683 4000
- Website
- bostonscientific.com
About Boston Scientific Corp
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scopes used for diagnostic and therapeutic procedures in the pancreaticobiliary system, in endoscopic retrograde cholangiopancreatography procedures, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention products; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, radiofrequency ablation, and intraosseous nerve ablation and deep brain stimulation systems. The company also provides technologies for diagnosing and treating a range of diseases and abnormalities of the heart; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, it offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose and treat forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
Boston Scientific Corp management
10- Mr. Michael F. MahoneyChairman, President & CEO · born 1965
- Mr. Jonathan R. MonsonExecutive VP & CFO · born 1974
- Mr. Vance R. Brown J.D.EVP, General Counsel & Corporate Secretary · born 1970
- Mr. Joseph M. FitzgeraldExecutive VP & Group President of Cardiovascular · born 1964
- Mr. Arthur Crosswell ButcherExecutive VP and Group President of MedSurg & Asia Pacific · born 1971
- Mr. Paudie O'ConnorExecutive Vice President of Global Operations · born 1968
- Ms. Emily M. WoodworthSenior VP, Global Controller & Chief Accounting Officer · born 1978
- Mr. Adam SmithGeneral Manager of Global Sales & Marketing
- Ms. Miriam O'sullivanSenior VP & Chief Human Resources Officer · born 1981
- Ms. Brenda BeckerSenior Vice President of Global Government Affairs · born 1960